ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Portland, OR, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Portland, Oregon, United States and 43 other locations

with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) wi...

Enrolling
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: pemetrexed
Drug: LBL-007

Phase 2

BeiGene
BeiGene

Portland, Oregon, United States and 60 other locations

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Portland, Oregon, United States and 157 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Portland, Oregon, United States and 123 other locations

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Not yet enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Salem, Oregon, United States and 219 other locations

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small c ...

Active, not recruiting
Non-Small-Cell Lung Cancer
Drug: Amivantamab
Drug: Carboplatin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Portland, Oregon, United States and 72 other locations

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Portland, Oregon, United States and 252 other locations

Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks), administered prior to starting concurrent definitive chemoradiatio...

Active, not recruiting
Non-small Cell Carcinoma
Lung Cancer
Drug: Consolidation durvalumab
Drug: Induction Durvalumab

Phase 2

Rachel Sanborn

Portland, Oregon, United States and 4 other locations

alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung ...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Pemetrexed/Carboplatin
Drug: Pemetrexed/Cisplatin

Phase 3

AstraZeneca
AstraZeneca

Vancouver, Washington, United States and 152 other locations

The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: crizotinib
Drug: X-396 (ensartinib)

Phase 3

Xcovery

Portland, Oregon, United States and 71 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems